Your browser doesn't support javascript.
loading
Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma.
Mouabbi, Jason A; Raghavendra, Akshara Singareeka; Bassett, Roland L; Christgen, Matthias; Middleton, Lavinia; Teshome, Mediget; Nasrazadani, Azadeh; Hortobagyi, Gabriel; Hassan, Amy; Tripathy, Debasish; Layman, Rachel M.
Affiliation
  • Mouabbi JA; Department of Breast Medical Oncology, Unit 1354, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of General Oncology, Unit 462, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: jamouabbi@mdanderson.org.
  • Raghavendra AS; Department of Breast Medical Oncology, Unit 1354, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of General Oncology, Unit 462, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Bassett RL; Department of Biostatistics, Unit 1411, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of General Oncology, Unit 462, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Christgen M; Institute of Pathology, Hannover Medical School, Hannover, Germany; Department of General Oncology, Unit 462, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Middleton L; Department of Pathology, Unit 0085, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of General Oncology, Unit 462, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Teshome M; Department of Breast Surgical Oncology, Unit 1434, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of General Oncology, Unit 462, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Nasrazadani A; Department of Breast Medical Oncology, Unit 1354, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of General Oncology, Unit 462, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hortobagyi G; Department of Breast Medical Oncology, Unit 1354, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of General Oncology, Unit 462, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hassan A; Department of Pathology, Unit 0085, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of General Oncology, Unit 462, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Tripathy D; Department of Breast Medical Oncology, Unit 1354, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of General Oncology, Unit 462, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Layman RM; Department of Breast Medical Oncology, Unit 1354, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of General Oncology, Unit 462, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Eur J Cancer ; 191: 113250, 2023 09.
Article in En | MEDLINE | ID: mdl-37573674
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Carcinoma in Situ / Carcinoma, Lobular / Breast Carcinoma In Situ Type of study: Prognostic_studies Limits: Female / Humans Language: En Journal: Eur J Cancer Year: 2023 Document type: Article Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Carcinoma in Situ / Carcinoma, Lobular / Breast Carcinoma In Situ Type of study: Prognostic_studies Limits: Female / Humans Language: En Journal: Eur J Cancer Year: 2023 Document type: Article Country of publication: United kingdom